Merlano, M.C.; Paccagnella, M.; Denaro, N.; Abbona, A.; Galizia, D.; Sangiolo, D.; Gammaitoni, L.; Fiorino, E.; Minei, S.; Bossi, P.;
et al. Baseline Values of Circulating IL-6 and TGF-β Might Identify Patients with HNSCC Who Do Not Benefit from Nivolumab Treatment. Cancers 2023, 15, 5257.
https://doi.org/10.3390/cancers15215257
AMA Style
Merlano MC, Paccagnella M, Denaro N, Abbona A, Galizia D, Sangiolo D, Gammaitoni L, Fiorino E, Minei S, Bossi P,
et al. Baseline Values of Circulating IL-6 and TGF-β Might Identify Patients with HNSCC Who Do Not Benefit from Nivolumab Treatment. Cancers. 2023; 15(21):5257.
https://doi.org/10.3390/cancers15215257
Chicago/Turabian Style
Merlano, Marco Carlo, Matteo Paccagnella, Nerina Denaro, Andrea Abbona, Danilo Galizia, Dario Sangiolo, Loretta Gammaitoni, Erika Fiorino, Silvia Minei, Paolo Bossi,
and et al. 2023. "Baseline Values of Circulating IL-6 and TGF-β Might Identify Patients with HNSCC Who Do Not Benefit from Nivolumab Treatment" Cancers 15, no. 21: 5257.
https://doi.org/10.3390/cancers15215257
APA Style
Merlano, M. C., Paccagnella, M., Denaro, N., Abbona, A., Galizia, D., Sangiolo, D., Gammaitoni, L., Fiorino, E., Minei, S., Bossi, P., Licitra, L., & Garrone, O.
(2023). Baseline Values of Circulating IL-6 and TGF-β Might Identify Patients with HNSCC Who Do Not Benefit from Nivolumab Treatment. Cancers, 15(21), 5257.
https://doi.org/10.3390/cancers15215257